



02-04-08

1638  
14w  
#

Attorney's Docket No.: 23048-004006/402E

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Gyula Hadlaczky et al.      Art Unit : 1638  
Serial No. : 09/724,726      Examiner : Georgia Helmer  
Filed : November 28, 2000      Cust. No. : 20985  
Conf. No. : 7776  
Title : ARTIFICIAL CHROMOSOMES, USES THEREOF AND METHODS FOR  
PREPARING ARTIFICIAL CHROMOSOMES

**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Dear Sir:

Transmitted herewith are a Supplemental Information Disclosure Statement (7 pages), Form PTO-1449 (1 page), cited non U.S. patent documents listed on the form PTO-1449, documents listed in table of Supplementary Information Disclosure Statement (25 documents), a check in the amount of \$180.00, and a return postcard for filing in connection with the above-identified application.



The Commissioner is hereby authorized to charge the fee for the extension of time and any other fee that may be due in connection with this and the attached papers or with this application during its entire pendency to Deposit Account No. 06-1050. A duplicate of this sheet is enclosed.

Respectfully submitted,

Stephanie Seidman  
Reg. No. 33,779

Attorney Docket No. 23048-004006/402E  
**Address all correspondence to:**  
Stephanie Seidman  
Fish & Richardson P.C.  
12390 El Camino Real  
San Diego, California 92130  
Telephone: (858) 678-4777  
Facsimile: (202) 626-7796  
email: seidman@fr.com

CERTIFICATE OF MAILING BY "EXPRESS MAIL"  
"Express Mail" Mailing Label Number EV 965983166 US  
Date of Deposit January 31, 2008  
I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.

Stephanie Seidman



accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

In accordance with the requirements of 37 C.F.R. §1.98, the following documents are provided for consideration by the Examiner:

1) Office Action, issued September 30, 2003, in connection with U.S. Patent Application Serial No. 09/724,872 (Attorney Docket No. 23048-004007/402F), which is a continuation of U.S. Patent Application Serial No. 08/835,682 and ultimately claims priority to U.S. Patent Application Serial No. 08/629,822.

2-3) Office Actions, issued August 25, 2004 and May 19, 2005, in connection with U.S. Patent Application Serial No. 10/125,767 (Attorney Docket No. 17084-004011/402J), which is a divisional of U.S. Patent Application Serial No. 09/724,693 and ultimately claims priority to U.S. Patent Application Serial No. 08/629,822.

4-6) Office Actions, issued February 24, 2006, January 4, 2007 and October 18, 2007, in connection with U.S. Patent Application Serial No. 10/151,078 (Attorney Docket No. 17084-004012/402K), which is a divisional of U.S. Patent Application Serial No. 09/724,872 and ultimately claims priority to U.S. Patent Application Serial No. 08/629,822.

7) Office Action, issued October 5, 2004, in connection with U.S. Patent Application Serial No. 10/151,081 (Attorney Docket No. 17084-004013/402L), which is a divisional of U.S. Patent Application Serial No. 09/799,462 and ultimately claims priority to U.S. Patent Application Serial No. 08/629,822.

8-9) Office Actions, issued February 14, 2006 and June 21, 2007, in connection with U.S. Patent Application Serial No. 10/287,313 (Attorney Docket No. 17084-004015/402N), which is a divisional of U.S. Patent Application Serial No. 09/724,726 and ultimately claims priority to U.S. Patent Application Serial No. 08/629,822.

10) Office Action, issued July 11, 2007, in connection with U.S. Patent Application Serial No. 11/355,288 (Attorney Docket No. 23048-004019/402R), which is a continuation of U.S. Patent Application Serial No. 09/724,872 and ultimately claims priority to U.S. Patent Application Serial No. 08/629,822.

11) Office Action, issued July 11, 2007, in connection with U.S. Patent Application Serial No. 11/592,435 (Attorney Docket No. 17084-004020/402S), which is a continuation of U.S. Patent Application Serial No. 10/808,689 and ultimately claims priority to U.S. Patent Application Serial No. 08/629,822.

12) Translation of Office Action, issued May 8, 2007, in connection with Japanese Patent Application No. 2003-029830 (Attorney Docket No. 17084-004JP2/402BJP), which is a divisional of Japanese Patent Application No. 538116/97, now issued patent JP 3754457 (Attorney Docket No. 17084-004JP1/402JP), which is a national stage filing of International Patent Application No. PCT/US97/05911.

13) Translation of Office Action, issued May 8, 2007, in connection with Japanese Patent Application No. 2004-227303 (Attorney Docket No. 17084-004JP3/402CJP), which is a divisional of Japanese Patent Application No. 2003-029830.

14-15) Translations of Office Actions, issued December 13, 2005 and October 9, 2007, in connection with Japanese Patent Application No. 2005-210480 (Attorney Docket No. 23048-004JP4/402DJP), which is a divisional of Issued Japanese Patent No. 3754457.

16) Office Action, issued November 27, 2007, in connection with U.S. Patent Application Serial No. 11/417,983 (Attorney Docket No. 17084-018006/416F), which is a divisional of U.S. Patent Application Serial No. 09/815,979.

17) Office Action, issued June 29, 2005, in connection with U.S. Patent Application Serial No. 10/161,408 (Attorney Docket No. 23048-021001/419), which claims priority to U.S. Provisional Application Serial Nos. 60/294,687 and 60/296,329.

18) International Preliminary Examination Report, issued July 30, 2003, in connection with International Patent Application No. PCT/US02/17451 (Attorney Docket No. 17084-021WO1/419PC), which claims priority to U.S. Provisional Application Serial Nos. 60/294,687 and 60/296,329.

19) Examination Report, issued February 24, 2006, in connection with European Patent Application No. 02739627.4 (Attorney Docket No. 23048-021EP1/419EP), which is a national stage filing of International Patent Application No. PCT/US02/17451.

20) Examination Report, issued October 9, 2006, in connection with Australian Patent Application No. 2002312268 (Attorney Docket No. 23048-021AU1/419AU), which is a national stage filing of International Patent Application No. PCT/US02/17451.

21) Office Action, issued April 7, 2006, in connection with U.S. Patent Application Serial No. 10/161,403 (Attorney Docket No. 17084-022001/420), which claims priority to U.S. Provisional Application Serial Nos. 60/294,758 and 60/366,891.

22) Office Action, issued December 31, 2007, in connection with U.S. Patent Application Serial No. 11/082,154 (Attorney Docket No. 17084-022003/420C), which is a continuation of U.S. Patent Application Serial No. 10/161,403.

In addition, copies of other documents are provided (documents 23-25). The table below lists Documents 1-25 and includes a column that provides a space next to each document to be considered, for the Examiner's initials.

Examiner Initial	Document No.	Document
	1	Office Action, issued September 30, 2003, in connection with U.S. Patent Application Serial No. 09/724,872
	2	Office Action, issued August 25, 2004, in connection with U.S. Patent Application Serial No. 10/125,767
	3	Office Action, issued May 19, 2005, in connection with U.S. Patent Application Serial No. 10/125,767
	4	Office Action, issued February 24, 2006, in connection with U.S. Patent Application Serial No. 10/151,078
	5	Office Action, issued January 4, 2007, in connection with U.S. Patent Application Serial No. 10/151,078
	6	Office Action, issued October 18, 2007, in connection with U.S. Patent Application Serial No. 10/151,078
	7	Office Action, issued October 5, 2004, in connection with U.S. Patent Application Serial No. 10/151,081
	8	Office Actions, issued February 14, 2006, in connection with U.S. Patent Application Serial No. 10/287,313
	9	Office Action, issued June 21, 2007, in connection with U.S. Patent Application Serial No. 10/287,313
	10	Office Action, issued July 11, 2007, in connection with U.S. Patent Application Serial No. 11/355,288
	11	Office Action, issued July 11, 2007, in connection with U.S. Patent Application Serial No. 11/592,435
	12	Translation of Office Action, issued May 8, 2007, in connection with Japanese Patent Application No. 2003-029830
	13	Translation of Office Action, issued May 8, 2007, in connection with Japanese Patent Application No. 2004-227303
	14	Translation of Office Action, issued December 13, 2005, in connection with Japanese Patent Application No. 2005-210480
	15	Translation of Office Action, issued October 9, 2007, in connection with Japanese Patent Application No. 2005-210480
	16	Office Action, issued November 27, 2007, in connection with U.S. Patent Application Serial No. 11/417,983
	17	Office Action, issued June 29, 2005, in connection with U.S. Patent Application Serial No. 10/161,408
	18	International Preliminary Examination Report, issued July 30, 2003, in connection with International Patent Application No. PCT/US02/17451
	19	Examination Report, issued February 24, 2006, in connection with European Patent Application No. 02739627.4

Examiner Initial	Document No.	Document
	20	Examination Report, issued October 9, 2006, in connection with Australian Patent Application No. 2002312268
	21	Office Action, issued April 7, 2006, in connection with U.S. Patent Application Serial No. 10/161,403
	22	Office Action, issued December 31, 2007, in connection with U.S. Patent Application Serial No. 11/082,154
	23	Basu et al., "Artificial and engineered chromosomes: non-integrating vectors for gene therapy", Trends Mol. Med. 11:251-258 (2005)
	24	Henikoff S, "Heterochromatin function in complex genomes", Biochemica et Biophysica Reviews on Cancer 1470(1): 1-8 (2000)
	25	Henning <i>et al.</i> , "Human artificial chromosomes generated by modification of a yeast artificial chromosome containing both human alpha satellite and single-copy DNA sequences", Proc Natl Acad Sci U S A. Jan 19;96(2):592-7 (1999)

Applicant makes known to the Examiner ownership status of the following U.S applications which are commonly owned and/or have one or more inventors in common.

The following applications, including the instant application, designate two inventors, Aladar Szalay and Gyula Hadlaczky and ultimately have two assignees, Glaxo Group Limited and The Biological Research Center of the Hungarian Academy of Sciences. Gyula Hadlaczky assigned to The Biological Research Center of the Hungarian Academy of Sciences. Aladar Szalay assigned to American Gene Therapy, Inc. and Loma Linda University. American Gene Therapy, Inc. and Loma Linda University assigned to Chromos Molecular Systems. Glaxo Group Limited has purchased the rights of Chromos Molecular Systems. Thus, the following applications and the instant application have joint inventors and two assignees.

<u>U.S.S.N.(App. No.)</u>	<u>Filing Date</u>	<u>Docket No.</u>
08/629,822	04/10/96	17084-004001/402
09/096,648	06/12/98	17084-004002/402A
08/682,080	07/15/96	17084-004003/402B
08/695,191	08/07/96	17084-004004/402C
08/835,682	04/10/97	17084-004005/402D
09/724,726	11/28/00	23048-004006/402E
09/724,872	11/28/00	23048-004007/402F
09/724,693	11/28/00	17084-004008/402G
09/799,462	03/05/01	17084-004009/402H
09/836,911	04/17/01	17084-004010/402I
10/151,078	05/16/02	17084-004012/402K
10/151,081	05/16/02	17084-004013/402L
10/287,313	11/01/02	23048-004015/402N
10/782,129	02/18/04	17084-004016/402O

Applicant : Gyula Hadlaczký et al.  
Serial No. : 09/724,726  
Filed : November 28, 2000

Attorney's Docket No.: 23048-004006/402E  
Supplemental Information Disclosure Statement

11/284,877	11/21/05	23048-004018/402Q
11/355,288	02/14/06	23048-004019/402R

The following applications designate one inventor, Gyula Hadlaczký and one assignee, The Biological Research Center of the Hungarian Academy of Sciences. Gyula Hadlaczký assigned to The Biological Research Center of the Hungarian Academy of Sciences.

<u>U.S.S.N.(App. No.)</u>	<u>Filing Date</u>	<u>Docket No.</u>
10/125,767	04/17/02	17084-004011/402J
10/219,694	08/14/02	23048-004014/402M
10/808,689	03/24/04	23048-004017/402P
11/592,435	11/02/06	23048-004020/402S

The following applications designate three inventors, Carl Perez, Steven Fabijanski, and Edward Perkins, and ultimately two assignees, Chromos Molecular Systems, Inc. and Agrisoma, LLC. Carl Perez and Edward Perkins assigned to Chromos Molecular Systems, Inc. Glaxo Group Limited has purchased the rights of Chromos Molecular Systems. Steven Fabijanski assigned to Agrisoma, LLC. Thus, the following applications have joint inventors and two assignees.

<u>U.S.S.N.(App. No.)</u>	<u>Filing Date</u>	<u>Docket No.</u>
10/161,408	05/30/02	23048-021001/419
11/321,257	12/28/05	23048-021002/419B

The following applications designate three inventors, Edward Perkins, Carl Perez, Michael Lindenbaum, Amy Greene, Josephine Leung, Elena Fleming, Sandra Stewart, and Joan Shellard, and one assignee, Chromos Molecular Systems, Inc. Edward Perkins, Carl Perez, Michael Lindenbaum, Amy Greene, Josephine Leung, Elena Fleming, Sandra Stewart, and Joan Shellard assigned to Chromos Molecular Systems, Inc. Glaxo Group Limited has purchased the rights of Chromos Molecular Systems. Thus, the following applications have joint inventors and one assignee.

<u>U.S.S.N.(App. No.)</u>	<u>Filing Date</u>	<u>Docket No.</u>
10/161,403	05/30/02	17084-022001/420
11/006,076	12/06/04	17084-022002/420B
11/082,154	03/15/05	23048-022003/420C
11/480,175	06/29/06	17084-022004/420D

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an


Applicant : Gyula Hadlaczky et al.  
Serial No. : 09/724,726  
Filed : November 28, 2000

Attorney's Docket No.: 23048-004006/402E  
Supplemental Information Disclosure Statement

admission by Applicant or Applicant's representative that any of the information, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(g) and (h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

Applicant respectfully requests that the Examiner review the foregoing references and they be made of record in the file history of the above-captioned application.

Respectfully submitted,



---

Stephanie Seidman  
Reg. No. 33,779

Attorney Docket No. 23048-004006/402E  
**Address all correspondence to:**  
Stephanie Seidman  
Fish & Richardson P.C.  
12390 El Camino Real  
San Diego, California 92130  
Telephone: (858) 678-4777  
Facsimile: (202) 626-7796  
email: seidman@fr.com